US4042678A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Water-soluble agents having mitogenic properties obtained from nocardia cells, and processes for the preparation thereof
Assignee: Bpifrance Financement SA
•
Filing: 1975-04-24
•
Granted: 1977-08-16
•
Expires: 1995-04-24
Abstract
Abstract The invention pertains to a mitrogenic agent and to a process for obtaining same. It comprises the steps of cultivating Nocardiae cells, collecting them, subjecting them to a treatment for rupturing the integrity of their walls, such as by lysis, discarding the solid residue and collecting the aqueous fraction, causing the peptidoglycane fragments contained in this aqueous fraction to be separated therefrom and recovering the remaining fraction containing the mitogenic agent.
Inventors
- 👤 born Sfartz Ciorbaru Rita
- 👤 born Chosson Adam Arlette
- 👤 Jean-Francois Petit
- 👤 Edgar Lederer
- 👤 born Rousselot Damais Chantal
- 👤 Louis Chedid
- 👤 Constantin Bona
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 20:02
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/66; A61K35/74; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/822; Y10S435/872; Y10S436/00; Y10S436/823; Y10S436/826
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
101 words
In the process for preparing a water-soluble agent which comprises treating an aqueous suspension of delipidated Nocardia cells with a muramidase to free the mitogenic agent and immunological non-specific adjuvant peptidoglycane and other adjuvant fragments that were contained therein, separating the solid fraction from the mixture, recovering the aqueous mixture containing the mitogenic agent and immunological non-specific adjuvant peptidoglycane fragments, the improvement comprising: separating from the aqueous mixture the portion containing the adjuvant peptidoglycane fragments, which adjuvant is soluble in concentrated acetic acid, and recovering the remaining fraction which contains the mitogenic agent, said agent being insoluble in concentrated acetic acid.
Claim 2
Dependent Claim
101 words
In the process for preparing a water-soluble agent which comprises treating an aqueous suspension of delipidated Nocardia cells with a muramidase to free the mitogenic agent and immunological non-specific adjuvant peptidoglycane and other adjuvant fragments that were contained therein, separating the solid fraction from the mixture, recovering the aqueous mixture containing the mitogenic agent and immunological non-specific adjuvant peptidoglycane fragments, the improvement comprising: separating from the aqueous mixture the portion containing the adjuvant peptidoglycane fragments, which adjuvant is soluble in concentrated acetic acid, and recovering the remaining fraction which contains the mitogenic agent, said agent being insoluble in concentrated acetic acid.
Claim 3
Dependent Claim
22 words
The process of claim 1 which comprises the additional step of lyophilizing the aqueous portion before separating the adjuvant peptidoglycane fragments therefrom.
Claim 4
Dependent Claim
16 words
The process of claim 2 which comprises the additional step of delipidating the cells before lyophilizing.
Claim 5
Dependent Claim
28 words
The process of claim 1 which comprises the additional step of purifying by filtration with a molecular sieve the aqueous portion before separating the adjuvant peptidoglycane fragments therefrom.
Claim 6
Dependent Claim
15 words
The process of claim 4 wherein said fractionating comprises filtering through a molecular sieve column.
Claim 7
Dependent Claim
26 words
The process of claim 1 wherein separating the adjuvant peptidoglycane fragments from the aqueous portion is performed by suspending the aqueous portion in concentrated acetic acid.
Claim 8
Dependent Claim
22 words
The process of claim 1 which comprises the further step of separating the supernatant from the deposit prior to collecting the deposit.
Claim 9
Dependent Claim
30 words
The process of claim 6 which comprises the further step of recovering by redissolving in water the acetic acid-insoluble fraction which contains the mitogenic agent, and which is water soluble.
Claim 10
Dependent Claim
14 words
The process of claim 8 wherein the recovery step is carried out by gravity.
Claim 11
Dependent Claim
47 words
A mitogenic agent from delipidated Nocardia cells which is free of peptidoglycane fragments which have adjuvant activity, are soluble in concentrated acetic acid and which agent is active in vivo, water-soluble concentrated acetic acid-insoluble and which is capable of stimulating B-lymphocytes and the proliferation of stem cells.
Claim 12
Dependent Claim
47 words
A mitogenic agent from delipidated Nocardia cells which is free of peptidoglycane fragments which have adjuvant activity, are soluble in concentrated acetic acid and which agent is active in vivo, water-soluble concentrated acetic acid-insoluble and which is capable of stimulating B-lymphocytes and the proliferation of stem cells.
Claim 13
Dependent Claim
9 words
The aqueous solution of the agent of claim 10.
Claim 14
Dependent Claim
8 words
The agent of claim 10 which is non-toxic.
Claim 15
Dependent Claim
22 words
A pharmaceutical composition which is a non-toxic, injectable preparation of the agent of claim 10 in combination with a pharmaceutically acceptable carrier.
Claim 16
Dependent Claim
17 words
An immunological process for stimulating lyphocytes which comprises contacting them with the mitogenic composition of claim 10.
Claim 17
Dependent Claim
18 words
An immunological process for stimulating lymphocytes in vivo by administering the agent of claim 10 to warm-blooded animals.
Claim 18
Dependent Claim
20 words
An immunological process for stimulating the formation of stem cells which comprises contacting them with the agent of claim 10.
Claim 19
Dependent Claim
20 words
An immunological process for stimulating the proliferation of stem cells which comprises contacting them with the agent of claim 10.
Claim 20
Dependent Claim
32 words
An immunological process for treating bone marow deficiency diseases due to a deficiency in stem cells which comprises administering an injectable solution of the agent of claim 10 to a warm-blooded mammal.
Claim 21
Dependent Claim
23 words
An immunological process for diagnosing immunodeficiencies with regard to antibody-producing cells which comprises contacting lymph organ cells with the agent of claim 10.
Claim 22
Dependent Claim
38 words
An immunological process for treating bone marrow deficiency diseases due to deficiency in stem cells which comprises administering a dose of the agent of claim 10 effective to stimulate lymphocytes and to stimulate the prolification of stem cells.
Claim 23
Dependent Claim
13 words
The pharmaceutical composition of claim 13 wherein the carrier is an aqueous solution.
Claim 24
Dependent Claim
14 words
The pharmaceutical composition of claim 21 wherein the composition is free of oily carrier.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-08-15 | 1981-02-14 | 1981-08-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-08-15 | 1985-02-14 | 1985-08-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-08-15 | 1989-02-14 | 1989-08-16 | $7700.00 | Window Closed / Lapsed |